As the COVID-19 pandemic continues, so have regulatory actions by the U.S. Food and Drug Administration (FDA) affecting the regenerative medicine industry.  This includes the issuance of agency demand letters also known as “warning” letters that are served on parties for alleged violations of federal law.  Historically, such actions were not rendered until an in-person